{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:07:02Z","timestamp":1758816422033,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s10147-020-01706-w","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T07:02:51Z","timestamp":1590217371000},"page":"1718-1725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Suppressive effect upon carboplatin hypersensitivity reaction via pegylated liposomal doxorubicin combination therapy"],"prefix":"10.1007","volume":"25","author":[{"given":"Kyoko","family":"Shimada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-8091","authenticated-orcid":false,"given":"Shoji","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Shibutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasumi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoatsu","family":"Jimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Kitai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaya","family":"Shiozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,23]]},"reference":[{"key":"1706_CR1","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21:3194\u20133200","journal-title":"J Clin Oncol"},{"key":"1706_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","volume":"27","author":"MA Bookman","year":"2009","unstructured":"Bookman MA, Brady MF, McGuire WP et al (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419\u20131425","journal-title":"J Clin Oncol"},{"key":"1706_CR3","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","volume":"17","author":"M Markman","year":"1999","unstructured":"Markman M, Kennedy A, Webster K et al (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17:1141\u20131145","journal-title":"J Clin Oncol"},{"key":"1706_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ygyno.2006.10.047","volume":"105","author":"JR Schwartz","year":"2007","unstructured":"Schwartz JR, Bandera C, Bradley A et al (2007) Does the platibum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants\u2019 Hospital. Gynecol Oncol 105:81\u201383","journal-title":"Gynecol Oncol"},{"key":"1706_CR5","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ygyno.2006.04.002","volume":"103","author":"M Navo","year":"2006","unstructured":"Navo M, Kunthur A, Badell ML et al (2006) Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 103:608\u2013613","journal-title":"Gynecol Oncol"},{"key":"1706_CR6","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2001.19.12.3126","volume":"19","author":"KM Zanotti","year":"2001","unstructured":"Zanotti KM, Rybicki LA, Kennedy AW et al (2001) Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19:3126\u20133129","journal-title":"J Clin Oncol"},{"key":"1706_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ygyno.2011.04.019","volume":"122","author":"F Joly","year":"2011","unstructured":"Joly F, Ray-Coquard I, Fabbro M et al (2011) Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 122:226\u2013232","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1706_CR8","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.3802\/jgo.2020.31.e15","volume":"31","author":"SJ Park","year":"2020","unstructured":"Park SJ, Kim J, Kim HS et al (2020) Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study. J Gynecol Oncol 31(2):e15","journal-title":"J Gynecol Oncol"},{"key":"1706_CR9","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323\u20133329","journal-title":"J Clin Oncol"},{"key":"1706_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","volume":"12","author":"HJ Lenz","year":"2007","unstructured":"Lenz HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12:601\u2013609","journal-title":"Oncologist"},{"issue":"3","key":"1706_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ygyno.2009.11.026","volume":"116","author":"M Markman","year":"2010","unstructured":"Markman M, Moon J, Wilczynski S et al (2010) Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol 116(3):323\u2013325","journal-title":"Gynecol Oncol"},{"issue":"10","key":"1706_CR12","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s10147-019-01471-5","volume":"24","author":"H Fujiwara","year":"2019","unstructured":"Fujiwara H, Ushijima K, Nagao S et al (2019) A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003\/intergroup study). Int J Clin Oncol 24(10):1284\u20131291","journal-title":"Int J Clin Oncol"},{"key":"1706_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jaip.2014.04.010","volume":"2","author":"A Banerji","year":"2014","unstructured":"Banerji A, Lax T, Guyer A et al (2014) Management of hypersensitivity reactions to carboplatin and paclitaxel in outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract 2:428\u2013433","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1706_CR14","first-page":"207084","volume":"20","author":"N Makrilia","year":"2010","unstructured":"Makrilia N, Syrigou E, Kaklamanos I et al (2010) Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 20:207084","journal-title":"Met Based Drugs"},{"key":"1706_CR15","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3389\/fphar.2017.00800","volume":"8","author":"YH Tai","year":"2017","unstructured":"Tai YH, Tai YJ, Hsu HC et al (2017) Risk factors of hypersensitivity to carboplatin in patients with gynecologic malignancies. Front Pharmacol 8:800","journal-title":"Front Pharmacol"},{"issue":"10214","key":"1706_CR16","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","volume":"394","author":"AR Clamp","year":"2019","unstructured":"Clamp AR, James EC, McNeish IA et al (2019) Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet 394(10214):2084\u20132095","journal-title":"Lancet"},{"issue":"7","key":"1706_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2165\/00003088-200140070-00005","volume":"40","author":"JM Harris","year":"2001","unstructured":"Harris JM, Martin NE, Modi M (2001) Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40(7):539\u2013551","journal-title":"Clin Pharmacokinet"},{"key":"1706_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ijpharm.2010.03.022","volume":"392","author":"H Koide","year":"2010","unstructured":"Koide H, Asai T, Hatanaka K et al (2010) T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of pegylated liposomes. Int J Pharm 392:218\u2013223","journal-title":"Int J Pharm"},{"issue":"6","key":"1706_CR19","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1097\/IGC.0000000000001280","volume":"28","author":"K LaVigne","year":"2018","unstructured":"LaVigne K, Hyman DM, Zhou QC et al (2018) A randomized trial of prophylactic extended carboplatin infusion to reduce hypersensitivity reactions in recurrent ovarian cancer. Int J Gynecol Cancer 28(6):1176\u20131182","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01706-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01706-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01706-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T23:34:37Z","timestamp":1621726477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01706-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,23]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1706"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01706-w","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2020,5,23]]},"assertion":[{"value":"25 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None of the authors report a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures related to this study were in accordance with the 1964 Helsinki Declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}